SAREPTA THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
SAREPTA THERAPEUTICS, INC. (SRPT) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$4.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$4.89M, a 102.43% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $350.86M.
- SAREPTA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$282.85M, a 261.75% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$179.95M, a 628.88% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$713.41M, a 382.83% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was $252.24M.
- SAREPTA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$535.98M.
- SAREPTA THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$703.49M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.89M 10-Q · filed 2026-08-05 | $365.75M 10-Q · filed 2026-08-05 | $63.12M derived: sum of 3 quarters · filed 2026-08-05 | -$116.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $350.86M 10-Q · filed 2026-05-06 | $68.01M derived: sum of 2 quarters · filed 2026-05-06 | -$111.94M derived: sum of 3 quarters · filed 2026-05-06 | $89.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$282.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$462.79M derived: sum of 2 quarters · filed 2026-03-02 | -$261.60M derived: sum of 3 quarters · filed 2026-08-05 | -$713.41M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$179.95M 10-Q · filed 2025-11-06 | $21.25M derived: sum of 2 quarters · filed 2026-08-05 | -$430.56M 10-Q · filed 2025-11-06 | -$251.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $201.19M 10-Q · filed 2026-08-05 | -$250.62M 10-Q · filed 2026-08-05 | -$71.45M derived: sum of 3 quarters · filed 2026-08-05 | -$37.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$447.51M 10-Q · filed 2026-05-06 | -$272.64M derived: sum of 2 quarters · filed 2026-05-06 | -$238.62M derived: sum of 3 quarters · filed 2026-05-06 | -$231.82M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $174.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $208.89M derived: sum of 2 quarters · filed 2026-03-02 | $215.69M derived: sum of 3 quarters · filed 2026-03-02 | $252.24M 10-K · filed 2026-03-02 |
| 2024-09-30 | $34.02M 10-Q · filed 2025-11-06 | $40.82M derived: sum of 2 quarters · filed 2025-11-06 | $77.37M 10-Q · filed 2025-11-06 | $123.03M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $6.80M 10-Q · filed 2025-08-06 | $43.35M 10-Q · filed 2025-08-06 | $89.00M derived: sum of 3 quarters · filed 2026-03-02 | $48.07M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $36.55M 10-Q · filed 2025-05-06 | $82.20M derived: sum of 2 quarters · filed 2026-03-02 | $41.27M derived: sum of 3 quarters · filed 2026-03-02 | |
| 2023-12-31 | $45.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.72M derived: sum of 2 quarters · filed 2026-03-02 | -$535.98M 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$40.94M 10-Q · filed 2024-11-06 | -$581.63M 10-Q · filed 2024-11-06 | ||
| 2022-12-31 | -$703.49M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |